Mitotech S.A. is a Luxembourg-based single-molecule biotechnology company with a portfolio of novel drugs for the treatment of age-related disorders undergoing early, middle and late stages of drug development. Their drug portfolio consists of an ophthalmic drug (Visomitin™) and a systemic drug (Plastomitin™) that both have their lead compound SkQ1 – a highly efficient mitochondria-targeted antioxidant – as their active ingredient.

Their core team is a unique fusion of cross-disciplinary scientific experts, seasoned clinical drug development professionals and experienced business managers. Using this blend of business skills, industry expertise and fundamental scientific knowledge their company aims to approach complex scientific problems, such as protection against cellular oxidative stress, and turn the results of biological research into a line-up of pharmaceutical products. Company’s mission is to leverage the break-through in delivering highly active antioxidants into mitochondria across a wide spectrum of age-related therapeutic indications and to deliver medications with this novel mechanism of action to millions of patients worldwide.